Boundless Bio Advances KOMODO-1 Trial with $108M Cash Runway
Event summary
- Boundless Bio's KOMODO-1 trial for BBI-940 is now open for enrollment, targeting ER+/HER2- breast cancer and TNBC-LAR patients.
- The company reported $107.6M in cash as of December 31, 2025, providing runway into the second half of 2028.
- R&D expenses decreased to $44.8M in 2025 from $55.3M in 2024, while net loss narrowed to $58.2M from $65.4M.
- Boundless ceased enrollment in the POTENTIATE trial to prioritize BBI-940 development.
The big picture
Boundless Bio's focus on ecDNA biology positions it in a niche segment of oncology targeting chromosomally unstable cancers. The company's decision to prioritize BBI-940 reflects a strategic shift toward a potentially first-in-class oral Kinesin degrader, aligning with broader industry trends toward targeted cancer therapies. The $108M cash runway provides a clear runway for clinical proof-of-concept, but execution risks remain.
What we're watching
- Clinical Execution
- How the pace of KOMODO-1 enrollment and data readouts will impact Boundless Bio's proof-of-concept timeline.
- Cash Management
- Whether the $108M cash runway will be sufficient to reach key milestones without additional funding.
- Competitive Positioning
- The strategic implications of discontinuing the POTENTIATE trial in favor of BBI-940.
Related topics